Search research articles
Contact Us
Filters
Showing results (411-420 of 566) with videos related to
Page
of 57
Sort By:
British Journal of Haematology
|
July 13, 2017
Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation
Eli Muchtar, Angela Dispenzieri, Martha Q Lacy, et al.
American Journal of Hematology
|
November 25, 2021
Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients
Patrick W Mellors, Taxiarchis Kourelis, Ronald S Go, et al.
Genetics in Medicine Open
|
December 13, 2024
Disparity in the detection of chromosome 15 centromere in patients of African ancestry with a plasma cell neoplasm
Alaa Koleilat, Hongwei Tang, Neeraj Sharma, et al.
American Journal of Hematology
|
July 8, 2023
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma
Saurabh Zanwar, Matthew Ho, Yi Lin, et al.
Leukemia & Lymphoma
|
May 18, 2019
Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma
Patrick W Mellors, Moritz Binder, Francis K Buadi, et al.
Blood
|
April 17, 2012
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial
Shaji K Kumar, Suzanne R Hayman, Francis K Buadi, et al.
Research Square
|
April 17, 2026
Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure
Angela Dispenzieri, Maximilian Steinhardt, Eli Muchtar, et al.
Blood
|
April 12, 2012
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
Angela Dispenzieri, Francis Buadi, Kristina Laumann, et al.
American Journal of Hematology
|
June 2, 2011
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial
Shaji K Kumar, Martha Q Lacy, Suzanne R Hayman, et al.
American Journal of Hematology
|
April 4, 2017
Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia
Surbhi Sidana, S Vincent Rajkumar, Angela Dispenzieri, et al.
Page
of 57
Search research articles
Search
Showing results (411-420 of 566) with videos related to
Sort By:
Page
of 57
British Journal of Haematology
|
July 13, 2017
Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation
Eli Muchtar, Angela Dispenzieri, Martha Q Lacy, et al.
American Journal of Hematology
|
November 25, 2021
Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients
Patrick W Mellors, Taxiarchis Kourelis, Ronald S Go, et al.
Genetics in Medicine Open
|
December 13, 2024
Disparity in the detection of chromosome 15 centromere in patients of African ancestry with a plasma cell neoplasm
Alaa Koleilat, Hongwei Tang, Neeraj Sharma, et al.
American Journal of Hematology
|
July 8, 2023
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma
Saurabh Zanwar, Matthew Ho, Yi Lin, et al.
Leukemia & Lymphoma
|
May 18, 2019
Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma
Patrick W Mellors, Moritz Binder, Francis K Buadi, et al.
Blood
|
April 17, 2012
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial
Shaji K Kumar, Suzanne R Hayman, Francis K Buadi, et al.
Research Square
|
April 17, 2026
Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure
Angela Dispenzieri, Maximilian Steinhardt, Eli Muchtar, et al.
Blood
|
April 12, 2012
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
Angela Dispenzieri, Francis Buadi, Kristina Laumann, et al.
American Journal of Hematology
|
June 2, 2011
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial
Shaji K Kumar, Martha Q Lacy, Suzanne R Hayman, et al.
American Journal of Hematology
|
April 4, 2017
Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia
Surbhi Sidana, S Vincent Rajkumar, Angela Dispenzieri, et al.
Page
of 57